CD4 count at Antiretroviral therapy initiation and the risk of loss to follow-up: Results from a multicentre cohort study

Journal of Epidemiology and Community Health

Volumn 70, Issue 6, 2016, Pages 549-555

  Grimsrud, Anna ^a   Cornell, Morna ^a   Schomaker, Michael ^a   Fox, Matthew P ^b,c   Orrell, Catherine ^a   Prozesky, Hans ^d,e   Stinson, Kathryn ^a,f   Tanser, Frank ^g   Egger, Matthias ^h   Myer, Landon ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COHORT ANALYSIS; DATABASE; DRUG; EXPANSION; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY; PROTEIN; PUBLIC SECTOR;

SOUTH AFRICA;

ANTIRETROVIRUS AGENT;

ADULT; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECTS; FEMALE; FOLLOW UP; HIV INFECTIONS; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT CARE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; SOUTH AFRICA; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONTINUITY OF PATIENT CARE; FEMALE; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84954306136     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2015-206629     Document Type: Article

References (33)

1. UNAIDS. The gap report. Geneva: UNAIDS, 2014
2. World Health Organization. Global update on HIV treatment 2013: results, impact and opportunities. Geneva: World Health Organization, 2013
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). Geneva: World Health Organization, 2006
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization, 2010
5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization, 2013
6. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization, 2015:78
7. Easterbrook PJ, Irvine CJ, Vitoria M, et al. Developing the 2013 WHO consolidated antiretroviral guidelines. AIDS 2014;28(Suppl 2):S93-100
8. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010;24:2263-70
9. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS Med 2011;6:e18453
10. Grimsrud A, Balkan S, Casas EC, et al. Outcomes of antiretroviral therapy over a 10-year period of expansion: a multicohort analysis of African and Asian HIV programs. J Acquir Immune Defic Syndr 2014;67:e55-66
11. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008;86:678-87
12. Brinkhof MW, Boulle A, Weigel R, et al. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med 2009;6:e1000066
13. Van Cutsem G, Ford N, Hildebrand K, et al. Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS Med 2011;6:e14684
14. Alamo ST, Colebunders R, Ouma J, et al. Return to normal life after AIDS as a reason for lost to follow-up in a community-based antiretroviral treatment program. J Acquir Immune Defic Syndr 2012;60:e36-45
15. HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions-towards evidence-based decision-making. PLoS Med 2012;9:e1001259
16. Clouse K, Pettifor A, Maskew M, et al. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS 2013;27:645-50
17. Cornell M, Technau K, Fairall L, et al. Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. S Afr Med J 2009;99:653-60
18. Egger M, Ekouevi DK, Williams C, et al. Cohort profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2012;41:1256-64
19. Grimsrud AT, Cornell M, Egger M, et al. Impact of definitions of loss to follow-up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFU. J Clin Epidemiol 2013;66:1006-13
20. Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med 2012;9:e1001304
21. Schomaker M, Gsponer T, Estill J, et al. Non-ignorable loss to follow-up: correcting mortality estimates based on additional outcome ascertainment. Stat Med 2014;33:129-42
22. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008;86:559-67
23. Boulle A, Schomaker M, May MT, et al. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. PLoS Med 2014;11: e1001718
24. Cornell M, Lessells R, Fox MP, et al. Mortality among adults transferred and lost to follow-up from antiretroviral therapy programmes in South Africa: a multicenter cohort study. J Acquir Immune Defic Syndr 2014;67:e67-75
25. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99
26. Adakun SA, Siedner MJ, Muzoora C, et al. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr 2013;62:317-21
27. Ford N, Kranzer K, Hilderbrand K, et al. Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho. AIDS 2010;24:2645-50
28. Chaiyachati KH, Ogbuoji O, Price M, et al. Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS 2014;28(Suppl 2):S187-204
29. Holmes C, Pillay Y, Mwango A, et al. Health systems implications of the 2013 WHO consolidated antiretroviral guidelines and strategies for successful implementation. AIDS 2014;28(Suppl 2):S231-9
30. Dorrington R, Bourne B, Bradshaw D, et al. The impact of HIV/AIDS on adult mortality in South Africa. Cape Town: Burden of Disease Research Unit, Medical Research Council, 2001
31. Johnson L, Estill J, Keiser O, et al. Do increasing rates of loss to follow-up in antiretroviral therapy programs imply deteriorating patient retention? Am J Epidemiol 2014;180:1208-12
32. The Presidency. Republic of South Africa, Statement on the meeting of the South African National AIDS Council (SANAC). 2011. www.thepresidency.gov.za/pebble.asp?relid=4650
33. World Health Organization. Retention in HIV Programmes defining the challenges and identifying solutions: meeting report, 13-15 September 2011. Geneva, 2012